CasNo.160970-54-7,Pharmaceutical Raw Material Powder Silodosin CAS 160970-54-7 Silodosin,Silodosin(160970-54-7) Suppliers

0	Negotiable

Min.Order :0
Purity: 99%

Keywords

Silodosin Silodosin 160970-54-7

Quick Details

Appearance:White to off-white powder
Application:An α1a-adrenoceptor antagonist. It is used in treatment of benign prostatic hypertophy.
PackAge:Aluminum foil bag,fluorinated bottles,carboard drums or as your special request.
ProductionCapacity:
Storage:Store in cool & dry place. Keep away from strong light Shelf Life2 years when properly stored.
Transportation:1) Door to Door Service by DHL/FEDEX/EMS/TNT for package under 45kgs, about 3~7 days delivery. 2) Port to Port Service by Air for package more than 45kgs, about 3~7 days delivery. 3) Port to Port...

Superiority:

1) Provide costomers with "one-stop"packaging service,from research,development,production,export and so on.
2) We have our own R&D and production base,equipped with advanced production equipment and precision testing the Unitef States Pharmacopoeia(USP),the Britis Pharmacopoeia(EP) and other international advanced standards.All products are through the KOSGER,HALAL certification,the ISO quality management system certification and the HACCP certification.
3) More than 12 years of export experience.
4)Competitive price in China market.

Details:

Silodosin is a kind of α- adrenergic receptor antagonists developed by Japanese Kissei pharmaceutical company. It has a very good therapeutic efficacy on treating the dysuria related to benign prostatic hyperplasia. The selective effect on urethra of Silodosin is 12 times and 7.4 times as high as that of prazosin and tamsulosin, respectively, which can significantly inhibit norepinephrine-induced contraction of the prostate; it has dose-dependent inhibition bladder activity excitation in the benign prostatic hypertrophy models of rats, and can also improve the pressure threshold of bladder contraction. These data have suggested that, in addition to helping improve bladder function, silodosin is also effective in alleviating the related symptoms associated with benign prostatic hypertrophy.
Compared with similar drugs such as prazosin and tamsulosin, silodosin has a high selectivity onn theα1A- receptors located in the prostate and bladder neck, while having a low affinity to theα1B- and α1D-receptor. It can block theα1A- receptors in these sites, and relax the smooth muscle, and thus leading to the improvement of urinary flow rate and the alleviation of BPH symptoms.
The selective binding to the α1A-receptor by silodosin has a higher selectivity compared to the binding to the cardiovascular associated receptors α1B, thus maximizing the activity of the target organ as well as minimizing the potential effect on blood pressure.